Literature DB >> 6615694

Enzyme induction with rifampicin; lipoproteins and drug binding to alpha 1-acid glycoprotein.

J Feely, M Clee, L Pereira, E Guy.   

Abstract

Hepatic enzyme induction has been reported to increase lignocaine binding, alpha 1-acid glycoprotein concentration and high density lipoprotein (HDL) cholesterol. In eight volunteers treated with rifampicin for 3 weeks there was no significant alteration in these three variables although their antipyrine clearance was significantly increased. In 10 patients with pulmonary tuberculosis treated with rifampicin (mean 5 months) the degree of serum protein binding of lignocaine, alpha 1-acid glycoprotein and HDL-cholesterol concentration was not different from that of matched control patients. These results suggest that differential induction of these variables may occur.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615694      PMCID: PMC1427971          DOI: 10.1111/j.1365-2125.1983.tb04986.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

2.  Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects.

Authors:  E Perucca; M Ruprah; A Richens; B K Park; D J Betteridge; A M Hedges
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

3.  Does rifampicin increase serum levels of testosterone and oestradiol by inducing sex hormone binding globulin capacity?

Authors:  M J Brodie; A R Boobis; M Gill; K Mashiter
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

4.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

5.  Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; A Arranto; C Ehnholm
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Effect of phenobarbitone on plasma apolipoprotein B and plasma high-density-lipoprotein cholesterol in normal subjects.

Authors:  P N Durrington
Journal:  Clin Sci (Lond)       Date:  1979-05       Impact factor: 6.124

7.  Lignocaine disposition in blood in epilepsy.

Authors:  P A Routledge; W W Stargel; A L Finn; A Barchowsky; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

8.  Increased toxicity and reduced clearance of lidocaine by cimetidine.

Authors:  J Feely; G R Wilkinson; C B McAllister; A J Wood
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

9.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  9 in total
  3 in total

Review 1.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

2.  Modification of inflammatory processes by phenobarbital in rats.

Authors:  F E Levy; L Chauvelot-Moachon; I Florentin; M Forest; C Poüs; C Fournier; J P Giroud
Journal:  Inflammation       Date:  1991-12       Impact factor: 4.092

Review 3.  Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia.

Authors:  Mikko Karpale; Janne Hukkanen; Jukka Hakkola
Journal:  Cells       Date:  2022-01-18       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.